Despite the success of coronary interventions in the treatment of stenosis due to coronary atherosclerosis, it behooves cardiologists to treat the underlying disease by decreasing patients' cholesterol levels. Intravascular ultrasound has made it possible to detect plaque accumulation not visible on angiography. Although advanced lesions that are fibrous and calcific can be treated with atherectomy and lasers, it is the soft, lipid-laden plaque that is particularly vulnerable to rupture and leads to coronary events. Therefore, attention must also focus on decreasing atherosclerotic progression in patients who have undergone coronary interventions. Studies have clearly shown the value of cholesterol reduction in decreasing coronary events. However, a review of cardiologists' practices shows that more aggressive lipid-lowering therapy is needed. One way to achieve this goal is to treat and monitor patients who have undergone revascularization procedures and to encourage patients to become more involved in their own care.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0002-9149(98)00199-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predicting Plaque Regression Based on Plaque Characteristics Identified by Optical Coherence Tomography: A Retrospective Study.
Photodiagnosis Photodyn Ther
January 2025
Department of Cardiology, Shanghai East Hospital of Clinical Medical College, Nanjing Medical University, Nanjing 211166, China; Department of Cardiology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Electronic address:
Background: Atherosclerosis is a lipid-driven, systemic immune-inflammatory disease characterized by the accumulation of plaque within the arterial walls. Plaque regression can occur following appropriate treatment interventions. Optical coherence tomography (OCT), a high-resolution imaging modality, is frequently employed to assess plaque morphology.
View Article and Find Full Text PDFNew Approaches to Lipoproteins for the Prevention of Cardiovascular Events.
J Atheroscler Thromb
December 2024
Victorian Heart Institute, Monash University.
Article Synopsis
- Atherosclerotic cardiovascular disease (ASCVD) is a major global health issue, with high levels of low-density lipoprotein cholesterol (LDL-C) linked to increased cardiovascular risk.
- Numerous studies confirm that lipid-lowering therapies (LLT) are effective; however, there is a gap between guidelines and actual clinical practice regarding LDL-C targets.
- The review suggests new strategies beyond traditional LDL-C management, such as combination therapies and emerging drugs, while also introducing the potential use of polygenic risk scores for personalized treatment approaches in ASCVD prevention.
LDL-cholesterol lowering agents (statins and PCSK9 inhibitors) and the risk of intracerebral hemorrhage: A network meta-analysis.
J Stroke Cerebrovasc Dis
January 2025
Department of Neurology, Chongqing University Three Gorges Hospital, Wanzhou, Chongqing 400016, China; School of Medicine, Chongqing University, Chongqing 404010, China. Electronic address:
Background And Purpose: Statin therapy reduces the risk of ischemic stroke; however, certain studies have observed an increased incidence of intracerebral hemorrhage (ICH). Moreover, proprotein convertase subtilisin/kexin type 9(PCSK-9) inhibitors have emerged as a powerful class of lipid-lowering medications, potentially with a lower propensity for causing hemorrhagic events. To investigate this matter further, we conducted a network meta-analysis of randomized controlled trials (RCTs) involving statins and PCSK-9 inhibitors that reported occurrences of ICH.
View Article and Find Full Text PDFEfficiency of fixed-dose combinations of statin and ezetimibe in the treatment of hypercholesterolemia.
Clin Investig Arterioscler
January 2025
Unidad de Cardiología, Hospital Universitario de Jaén, Jaén, España.
Objective: To estimate the clinical and economic benefits derived from increasing the use of fixed-dose combinations of high-intensity statins and ezetimibe in patients at high/very high cardiovascular risk, from the perspective of the Spanish National Health System (SNS).
Methods: A baseline scenario (current market shares) was compared with scenarios that increased the use of fixed-dose combinations (alternative: 30% increase; optimized: 69% increase). The potential annual increase in the number of controlled patients, cardiovascular events avoided and the associated savings in direct medical costs were estimated, including the cost of pharmacological treatment, follow-up, and managing cardiovascular events over a three-year time horizon.
Curbside Consult Optimizing Statin Therapy in the Elderly: A Personalized Approach to Cardiovascular Disease Prevention.
Cardiol Rev
January 2025
Departments of Cardiology and Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) play a vital role in managing and preventing cardiovascular disease, particularly in elderly populations who face elevated risks for atherosclerosis and related conditions. This review delves into the mechanisms of statin action, emphasizing their impact on low-density lipoprotein cholesterol levels, anti-inflammatory properties, and potential genetic factors influencing efficacy and drug tolerability. Consideration is given to statin intolerance and management strategies, drug interactions, and guidelines for primary and secondary prevention of cardiovascular events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!